DrugPatentWatch Database Preview
Horizon Therap Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for HORIZON THERAP, and what generic alternatives to HORIZON THERAP drugs are available?
HORIZON THERAP has three approved drugs.
There are fifteen US patents protecting HORIZON THERAP drugs.
There are eighty-seven patent family members on HORIZON THERAP drugs in twenty-eight countries and fifty-nine supplementary protection certificates in fourteen countries.
Summary for Horizon Therap
| International Patents: | 87 |
| US Patents: | 15 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 3 |
| Patent Litigation for Horizon Therap: | See patent lawsuits for Horizon Therap |
| PTAB Cases with Horizon Therap as patent owner: | See PTAB cases with Horizon Therap as patent owner |
Drugs and US Patents for Horizon Therap
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Horizon Therap | RAVICTI | glycerol phenylbutyrate | LIQUID;ORAL | 203284-001 | Feb 1, 2013 | RX | Yes | Yes | 10,183,002 | Start Trial | Start Trial | ||||
| Horizon Therap | RAVICTI | glycerol phenylbutyrate | LIQUID;ORAL | 203284-001 | Feb 1, 2013 | RX | Yes | Yes | 8,642,012 | Start Trial | Start Trial | ||||
| Horizon Therap | RAVICTI | glycerol phenylbutyrate | LIQUID;ORAL | 203284-001 | Feb 1, 2013 | RX | Yes | Yes | 10,183,003 | Start Trial | Start Trial | ||||
| Horizon Therap | RAVICTI | glycerol phenylbutyrate | LIQUID;ORAL | 203284-001 | Feb 1, 2013 | RX | Yes | Yes | 10,183,005 | Start Trial | Start Trial | ||||
| Horizon Therap | RAVICTI | glycerol phenylbutyrate | LIQUID;ORAL | 203284-001 | Feb 1, 2013 | RX | Yes | Yes | 9,326,966 | Start Trial | Start Trial | ||||
| Horizon Therap | RAVICTI | glycerol phenylbutyrate | LIQUID;ORAL | 203284-001 | Feb 1, 2013 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Horizon Therap | RAVICTI | glycerol phenylbutyrate | LIQUID;ORAL | 203284-001 | Feb 1, 2013 | RX | Yes | Yes | 9,962,359 | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Horizon Therap
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Horizon Therap | RAVICTI | glycerol phenylbutyrate | LIQUID;ORAL | 203284-001 | Feb 1, 2013 | 5,968,979 | Start Trial |
| Horizon Therap | BUPHENYL | sodium phenylbutyrate | POWDER;ORAL | 020573-001 | Apr 30, 1996 | 4,457,942 | Start Trial |
| Horizon Therap | BUPHENYL | sodium phenylbutyrate | TABLET;ORAL | 020572-001 | May 13, 1996 | 4,457,942 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for HORIZON THERAP drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Oral Liquid | 1.1 g/mL | ➤ Subscribe | 2013-11-19 |
International Patents for Horizon Therap Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Mexico | 2014003854 | Start Trial |
| Australia | 2019201811 | Start Trial |
| Japan | 2015514757 | Start Trial |
| Chile | 2014000783 | Start Trial |
| European Patent Office | 2846791 | Start Trial |
| Japan | 2012501329 | Start Trial |
| Portugal | 2330892 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Horizon Therap Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2822954 | 18C1035 | France | Start Trial | PRODUCT NAME: BICTEGRAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER BICTEGRAVIR DE SODIUM; REGISTRATION NO/DATE: EU/1/18/1289 20180625 |
| 2330892 | PA2016041 | Lithuania | Start Trial | PRODUCT NAME: GLICEROLIO FENILBUTIRATAS; REGISTRATION NO/DATE: EU/1/15/1062 20151127 |
| 0290047 | SPC/GB97/078 | United Kingdom | Start Trial | PRODUCT NAME: MANGAFODIPIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR MANGAFODIPIR TRISODIUM; REGISTERED: UK EU/1/97/040/001 19970522; UK EU/1/97/040/002 19970522 |
| 2330892 | 1690060-7 | Sweden | Start Trial | PRODUCT NAME: GLYCEROL PHENYLBUTYRATE; REG. NO/DATE: EU/1/15/1062 20151201 |
| 0579826 | 02C0041 | France | Start Trial | PRODUCT NAME: ERTAPENEM SODIUM; REGISTRATION NO/DATE: EU/1/02/216/001 20020418 |
| 0268956 | 1999C0030 | Belgium | Start Trial | PRODUCT NAME: RABEPRAZOLE SODIUM; NAT. REGISTRATION NO/DATE: 5532 IE 1 F 3 19990201; FIRST REGISTRATION: GB 10555/0010 19980508 |
| 0473687 | SPC/GB98/030 | United Kingdom | Start Trial | PRODUCT NAME: FOSPHENYTOIN SODIUM (3-HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER); REGISTERED: UK 0019/0157 19980204 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
